Pharmaceuticals

COVID-19 antiviral drugs market 2026–2035 evolving with continued focus on infectious disease preparedness

March 25, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Specific Antiviral Drugs For COVID 19 Market Over The Period 2026–2030?

The market size for specific antiviral drugs targeting covid 19 has expanded quickly in recent years. It is projected to increase from $15.23 billion in 2025 to $17.83 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 17.1%. Historically, this expansion can be linked to the rapid dissemination of covid-19, emergency use authorizations, the reliance on traditional antiviral drug classifications, limited global production capabilities, and high hospitalization rates.

The specific antiviral drugs for covid 19 market size is projected to experience swift expansion over the coming years. This market is anticipated to reach a valuation of $33.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.8%. The projected growth during this period can be ascribed to several factors, including the advancement of next-generation antiviral medications, an increase in collaborations between public and private entities, a rise in the uptake of preventive treatments, the broadening use of combination therapies, and the incorporation of personalized medicine strategies. Key trends expected during the forecast period encompass greater investment in the development of COVID-19 antiviral drugs, an increasing preference for oral antiviral tablets, an expansion of monoclonal antibody-based treatments, the widening of hospital and retail distribution networks, and a concentrated effort on providing targeted therapies for patients who are hospitalized or at high risk.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp

What Drivers Are Expected To Influence The Specific Antiviral Drugs For COVID 19 Market During The Forecast Period?

An increasing number of COVID-19 cases is projected to stimulate the expansion of the specific antiviral drugs for the COVID-19 market going forward. COVID-19 cases refer to individuals confirmed positive for the SARS-CoV-2 virus, which is the cause of COVID-19. This surge in COVID-19 cases is attributed to the emergence of new variants that demonstrate easier transmission and can partially evade immunity from vaccines or prior infections. Specific antiviral drugs for COVID-19 are beneficial in reducing the severity and duration of the illness, leading to improved patient outcomes and a lower overall burden from COVID-19 cases. For instance, in May 2025, the World Health Organization, a Switzerland-based global public health agency, indicated that the Eastern Mediterranean region’s test positivity rate surged from 4% to 17% in early 2025, surpassing the rate from the identical period in 2024. Therefore, the escalating number of COVID-19 cases fuels the growth of the specific antiviral drugs for the COVID-19 market.

How Is The Specific Antiviral Drugs For COVID 19 Market Divided Into Its Major Segments?

The specific antiviral drugs for covid 19 market covered in this report is segmented –

1) By Type: Tablet, Injection

2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment

3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies

4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets

2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections

How Are Trends Transforming The Specific Antiviral Drugs For COVID 19 Market Landscape?

Leading companies in the specific antiviral drugs for the COVID-19 market are concentrating on developing innovative treatments, such as oral antiviral therapies, to improve both accessibility and effectiveness of care. These oral antiviral therapies are medicines taken by mouth to prevent the replication of viruses like COVID-19, presenting a convenient and efficient treatment choice. For example, in March 2024, Shionogi And Co., a pharmaceutical company located in Japan, launched Xocova and received full standard approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the antiviral drug ensitrelvir. Additionally, this drug also provides post-exposure prophylaxis by considerably decreasing the risk of symptomatic COVID-19 among exposed individuals and reduces the length of symptoms with a positive safety record.

Who Are The Prominent Organizations Shaping The Specific Antiviral Drugs For COVID 19 Market?

Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.

Read the full specific antiviral drugs for covid 19 market report here:

https://www.thebusinessresearchcompany.com/report/specific-antiviral-drugs-for-covid-19-global-market-report

Which Region Is Forecast To Lead The Specific Antiviral Drugs For COVID 19 Market In Terms Of Market Size?

North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Specific Antiviral Drugs For COVID 19 Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24713&type=smp

Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2026, By The Business Research Company

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

The Antiviral And Antimicrobial Coatings Market Report 2026

https://www.thebusinessresearchcompany.com/report/the-antiviral-and-antimicrobial-coatings-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795